Mood disorders III Case Management Discussion including ECT. Majid Al- Desouki , MD Clinical Assistant Professor and Consultant. Huda.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Mood disorders IIICase Management Discussion including ECT
Majid Al-Desouki, MD
Clinical Assistant Professor and Consultant
Mood stabilizing agents
Fluoxetine (20-80 mg/d)
Paroxetine (20-50 mg/d)
Fluvoxamine & Sertraline (50-200 mg/d)
Central Nervous System
Dizziness, cognitive impairment,
insomnia, headache, tremor,changes in satiety and appetite
Autonomic Nervous System
Dry mouth, urinary retention,
blurred vision, sweating
Typical/1st generation = D2 receptor antagonist
Effective against +ve > -ve
Atypicals/2nd generation = Serotonin-dopamine antagonists
Effective against both +ve & -ve sx
Lower numbers indicate higher potency
Comparison between Different Atypical Antipsychotics
Associated with MAOIs.
Neuroleptic malignant syndrome
Autonomic instability, severe EPS, delirium, ↑CK, ARF, myoglobulinuria
Restlessness, myoclonus, ↑reflexes, tremors, confusion.
Due to combination of serotonergic agents
ECT is used to treat:
Although ECT is generally safe, risks and side effects may include: